Telix Pharmaceuticals H1 2026 Earnings Report

Telix Pharmaceuticals EPS Results

• Actual EPS: N/A
• Consensus EPS: $0.04
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Telix Pharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $479.63 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Telix Pharmaceuticals Announcement Details

• Quarter: H1 2026
• Date: 8/20/2026
• Time: Before Market Opens
• Conference Call Date: Wednesday, August 19, 2026
• Conference Call Time: 7:00PM ET

Telix Pharmaceuticals (NASDAQ:TLX) (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates. Its lead product for prostate cancer imaging, Illuccix® (TLX591-CDx), is a kit-based gallium-68 PSMA agent designed to simplify PET scan preparation in decentralized nuclear medicine settings. Telix is also advancing PSMA-targeted therapy using lutetium-177, as well as somatostatin receptor-directed compounds for neuroendocrine tumors. Other programs in earlier stages include radiolabeled antibodies and small molecules aimed at bladder, brain and renal cancers.

Headquartered in Melbourne, Australia, Telix maintains commercial and clinical operations across North America, Europe and Asia Pacific. The company has secured regulatory approvals and reimbursements in multiple regions for its imaging products, and is conducting pivotal trials in the U.S. and Europe to expand patient access. Telix collaborates with leading academic institutions and contract research organizations to support its global clinical development and aims to build a scalable manufacturing and distribution network for radiopharmaceuticals.

Since its founding in 2015, Telix has grown under the leadership of CEO Dr. Christian Behrenbruch, who brings experience in healthcare management and specialized radiopharmaceutical development. The management team combines expertise in drug development, nuclear medicine and commercial operations. Telix continues to explore strategic partnerships and licensing agreements to accelerate the adoption of targeted radiopharmaceuticals and establish a new standard of care for oncology patients.